CD14 and acute myeloid leukemia: Within the group of AML patients with mutated NPM1, CD14+ Monocyte percentage associated stronger with both BCL-2 protein abundance (R2 = 0.56, P < 0.001) than BCL-2 gene expression (R2 = 0.52) (Fig. 4c, d).